STOCK TITAN

Merck & Co., Inc. - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.

Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.

Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.

The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.

From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.

Rhea-AI Summary

Merck (NYSE: MRK) has received European Commission approval for WINREVAIR™ (sotatercept) to treat adult patients with pulmonary arterial hypertension (PAH) in WHO Functional Class II-III. WINREVAIR is the first activin signaling inhibitor therapy for PAH approved in Europe, designed to improve exercise capacity when used with other PAH therapies.

The approval is based on the Phase 3 STELLAR trial, which showed significant improvements in six-minute walk distance and reduced risk of death or clinical worsening. WINREVAIR demonstrated an 82% reduction in the risk of death or clinical worsening compared to background therapy alone.

WINREVAIR is administered as a subcutaneous injection every 3 weeks and can be self-administered with proper training. This approval is valid in all 27 EU member states, Iceland, Liechtenstein, and Norway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
Rhea-AI Summary

Merck (NYSE: MRK) has announced a definitive agreement to acquire CN201, a novel investigational clinical-stage bispecific antibody, from Curon Biopharmaceutical for an upfront payment of $700 million in cash. The deal includes potential milestone payments of up to $600 million. CN201 is a next-generation CD3xCD19 bispecific antibody currently in Phase 1 and Phase 1b/2 clinical trials for treating relapsed or refractory non-Hodgkin's lymphoma and B-cell acute lymphocytic leukemia.

Preliminary data suggests CN201 has activity in patients with relapsed or refractory B-cell hematologic malignancies and is well-tolerated. Merck plans to evaluate CN201 for B-cell malignancies and autoimmune diseases. The transaction is expected to close in Q3 2024, subject to regulatory approval. Merck anticipates recording a pre-tax charge of approximately $750 million, or $0.28 per share, in non-GAAP results upon closing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
-
Rhea-AI Summary

Merck (NYSE: MRK) has announced the discontinuation of its Phase 3 KeyVibe-008 trial, which was evaluating a fixed-dose combination of vibostolimab and pembrolizumab (KEYTRUDA®) with chemotherapy for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The decision was based on a recommendation from an independent Data Monitoring Committee after a pre-planned analysis showed the primary endpoint of overall survival met pre-specified futility criteria. Additionally, patients in the experimental arm experienced higher rates of adverse events compared to the control arm.

Despite this setback, Merck remains committed to advancing research in lung cancer treatment. The company is pursuing multiple registration-enabling studies, including the IDeate-Lung02 Phase 3 trial with Daiichi Sankyo, evaluating ifinatamab deruxtecan in relapsed SCLC. Merck is also exploring combinations with MK-6070, a DLL3-targeting T-cell engager, in SCLC patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
Rhea-AI Summary

Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK) have expanded their global collaboration to include MK-6070, an investigational DLL3-targeting T-cell engager. The companies will jointly develop and commercialize MK-6070 worldwide, except in Japan where Merck retains exclusive rights. This agreement builds on their existing partnership for three DXd antibody drug conjugates.

MK-6070 targets DLL3, highly expressed in small cell lung cancer (SCLC) and neuroendocrine tumors. The companies plan to evaluate MK-6070 in combination with ifinatamab deruxtecan (I-DXd) for SCLC patients. Merck will receive a $170 million upfront payment, and the companies will share R&D costs, commercialization expenses, and profits globally, except in Japan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Summary

Daiichi Sankyo and Merck have initiated the IDeate-Lung02 phase 3 trial for ifinatamab deruxtecan (I-DXd) in patients with relapsed small cell lung cancer (SCLC). This trial will evaluate the efficacy and safety of I-DXd compared to physician's choice of chemotherapy. I-DXd is a potential first-in-class B7-H3 directed antibody drug conjugate (ADC) jointly developed by both companies.

SCLC is an aggressive form of lung cancer with poor prognosis, accounting for 15% of lung cancer cases. The trial's initiation is based on promising results from a subgroup analysis of the IDeate-PanTumor01 phase 1/2 trial presented at the 2023 World Conference on Lung Cancer. This marks the second pivotal study in the Daiichi Sankyo-Merck collaboration, following the REJOICE-Ovarian01 phase 2/3 study for raludotatug deruxtecan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
-
Rhea-AI Summary

Merck (NYSE: MRK) reported strong second-quarter 2024 financial results with total worldwide sales of $16.1 billion, a 7% increase year-over-year. Excluding foreign exchange impacts, growth was 11%. KEYTRUDA sales grew 16% to $7.3 billion. GAAP EPS was $2.14, while Non-GAAP EPS was $2.28. The company successfully launched WINREVAIR in the US and received a positive EU opinion for adults with PAH. Merck also achieved significant milestones with its vaccines and announced positive trial results for clesrovimab.

Merck completed acquisitions of EyeBio and Elanco’s Aqua Business and raised its full-year 2024 financial outlook to $63.4-$64.4 billion in sales and expects Non-GAAP EPS between $7.94 and $8.04. The outlook reflects a one-time charge of $1.3 billion for the EyeBio acquisition.

Quarterly results highlighted a 7% increase in pharmaceutical sales driven by oncology, cardiovascular, and vaccine growth, despite declines in diabetes and virology segments. Animal Health sales rose 2%, with notable increases in Livestock products. GAAP net income was $5.46 billion compared to a loss of $5.98 billion last year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.81%
Tags
Rhea-AI Summary

Merck (NYSE: MRK) received a positive opinion from the European Medicines Agency's CHMP for KEYTRUDA in combination with Padcev as a first-line treatment for unresectable or metastatic urothelial carcinoma. The recommendation is based on the Phase 3 KEYNOTE-A39 trial, which showed significant improvements in overall survival and progression-free survival compared to platinum-based chemotherapy:

- 53% reduction in risk of death
- 55% reduction in risk of disease progression or death

A final decision by the European Commission is expected in Q3 2024. If approved, this will be KEYTRUDA's third bladder cancer indication in the EU. The combination was already approved in the U.S. in December 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
Rhea-AI Summary

Merck (NYSE: MRK) has announced its quarterly dividend for the fourth quarter of 2024. The Board of Directors has declared a dividend of $0.77 per share of the company's common stock. This dividend will be paid on October 7, 2024, to shareholders who are on record at the close of business on September 16, 2024. Merck, also known as MSD outside of the United States and Canada, continues to provide returns to its shareholders through consistent dividend payments, demonstrating the company's financial stability and commitment to investor value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
dividends
-
Rhea-AI Summary

Merck (NYSE: MRK) has announced positive topline results from its Phase 2b/3 clinical trial of clesrovimab (MK-1654), an investigational monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease. The trial met all primary safety and efficacy endpoints, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150.

Merck plans to present detailed findings at an upcoming scientific congress and file the data with global regulatory authorities. Dr. Paula Annunziato, senior vice president at Merck Research Laboratories, emphasized the significance of these results, noting that RSV is the leading cause of hospitalization for healthy infants globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
Rhea-AI Summary

Merck's commitment to health equity is highlighted through the story of Priya Agrawal, the company's vice president of health equity and partnerships. Agrawal's personal experiences with health disparities in her family motivated her career in medicine and public health. She joined Merck to launch Merck for Mothers, a global initiative aimed at reducing maternal mortality. Her career at Merck has included roles such as lead of vaccines and contraceptives in the UK, managing director for South Africa and Sub-Saharan Africa, and global head of HPV vaccines. Agrawal's ongoing mission is to advance health equity and improve access to healthcare globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none

FAQ

What is the current stock price of Merck & Co. (MRK)?

The current stock price of Merck & Co. (MRK) is $101.16 as of November 25, 2024.

What is the market cap of Merck & Co. (MRK)?

The market cap of Merck & Co. (MRK) is approximately 256.1B.

What are the main therapeutic areas Merck focuses on?

Merck focuses on several therapeutic areas including cardiometabolic diseases, cancer, and infections. They also have a significant vaccine business and an animal health division.

What is Merck for Mothers?

Merck for Mothers is Merck’s global initiative dedicated to improving maternal health. The program has reached over 30 million women with initiatives that promote safe, high-quality care during pregnancy and childbirth.

What are some of Merck’s key products in oncology?

Merck's oncology portfolio includes KEYTRUDA, an immunotherapy used to treat various cancers, including melanoma. KEYTRUDA has shown significant benefits when used in combination with other therapies.

How significant is Merck’s vaccine business?

Merck has a substantial vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their vaccines portfolio is a major contributor to their public health impact.

Where is Merck headquartered?

Merck is headquartered in Rahway, New Jersey, USA.

What percentage of Merck’s sales comes from the United States?

Approximately half of Merck's sales are generated in the United States.

What is Merck's approach to research and development?

Merck invests heavily in research and development with over 2,250 ongoing clinical trials. Their approach focuses on innovative treatments and combination regimens to address complex health challenges.

What recent achievements has Merck announced?

Merck recently surpassed its goal of reaching 25 million women with its maternal health initiative, Merck for Mothers, by reaching over 30 million women. Additionally, they have reported promising results from clinical trials involving KEYTRUDA.

Does Merck collaborate with other companies for research?

Yes, Merck is actively involved in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

What is the historical origin of Merck & Co., Inc.?

Merck & Co., Inc. originated from the Merck Group, which was founded in Germany in 1668. The American arm, now an independent company, was established to serve the United States and Canada.

Merck & Co., Inc.

NYSE:MRK

MRK Rankings

MRK Stock Data

256.11B
2.53B
0.06%
79.47%
1.04%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH